HR Execs on the Move

Relay Technology Management

www.relaytm.com

 
Relay has developed a proprietary software solution for stakeholders of the biopharmaceutical technology licensing and development process.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million
  • www.relaytm.com
  • 1 Cambridge Ctr Suite 600
    Cambridge, MA USA '02142
  • Phone: 877.207.3529

Executives

Name Title Contact Details

Similar Companies

Solugen

Solugen is a venture-backed biotech startup that replaces petroleum based products with plant-derived substitutes.

Hound Labs

Hound Labs combines science and technology in novel ways to improve health and wellness. The Company believes its ultra-sensitive and portable technologies will pave the way to practical and fair solutions for some of the leading public health and safety issues. In the coming month, Hound Labs will launch the HOUND® CANNABIS BREATHALYZER, which allows employers and law enforcement to identify recent cannabis in breath. Dr. Mike Lynn, an ER physician, reserve deputy sheriff, and former venture capitalist, founded Hound Labs in 2014.

bioStrategies Group

bioStrategies Group is a Chicago, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Levant Technologies

Levant Technologies is a Norman, OK-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Aruvant

Aruvant`s mission is to bring hope to patients living with rare diseases by developing life changing and potentially curative gene therapies, with a near-term focus on sickle cell disease. Aruvant is a part of the Roivant family of companies. We have a talented team with extensive experience in the development, manufacturing and commercialization of gene therapy products. We have an active research program with a lead product candidate in development for individuals suffering from sickle cell disease (SCD). Our lead product candidate, ARU-1801, an investigational lentiviral gene therapy, is currently in a clinical trial as a potential one-time curative treatment for SCD. Preliminary clinical data from the ongoing Phase 1/2 study demonstrated durable efficacy in reducing the negative impacts of SCD. We are preparing for the launch of our pivotal clinical trial in SCD. We continue to look for new people to add to our talented team.